UBS Group
AEGR

UBS Group’s Aegerion Pharmaceuticals AEGR Stock Holding History

UBS Group’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-64,000
Closed -$1.21M – 8895
2015
Q2 		$1.21M Buy
+64,000
New +$1.39M ﹤0.01% 3409

UBS Group's AEGR Position: Q4 2016 in Review

UBS Group sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 3,781 shares — an estimated $11K sold.

UBS Group first reported a position in AEGR in Q4 2014 and held it in 8 quarters. The position peaked at $272K in Q3 2015. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

  • UBS Group reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • UBS Group sold 3,781 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $11K.
  • UBS Group first reported a position in Aegerion Pharmaceuticals in Q4 2014 and held it in 8 quarters.
  • UBS Group's Aegerion Pharmaceuticals position peaked at $272K in Q3 2015.
  • 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.